Discussion {#s2}
==========

A key element in the pathogenesis and sustainment of RCC is activation of the PI3K/Akt/mTORC pathway, which promotes tumor growth through its enhancing effects on both angiogenesis and tumor cell proliferation. Everolimus and temsirolimus, TORC1-specific allosteric mTOR inhibitors, are approved for use in advanced RCC \[[@B1]--[@B3]\]. Whether the addition of PI3K inhibition to mTOR inhibition is safe and improves outcomes is unknown. BEZ235 is an orally available PI3K, mTORC1, and mTORC2 inhibitor. We sought to investigate the safety and tolerability of BEZ235 in advanced RCC.

This was a single-center, phase Ib trial with the standard 3 + 3 dose escalation design set up to test twice-daily administration of BEZ235 across three dose levels. The study was conducted in patients with advanced RCC of any subtype previously treated with at least one systemic regimen; enrollment required Eastern Cooperative Oncology Group (ECOG) performance status 0--1 and adequate organ function. A total of 10 patients were enrolled. The first 2 patients in the initial 400 mg b.i.d. dosing cohort experienced DLTs (grade 3 fatigue and rash in 1 patient, and intolerable grade 2 nausea, vomiting, mucositis, and fatigue in the other), prompting de-escalation of dose. Per protocol, a 200 mg b.i.d. dosing cohort was opened, which ultimately enrolled 6 patients. Only 1 experienced a DLT (intolerable grade 2 mucositis), and with an amendment to the protocol, a third dosing cohort of BEZ235 300 mg b.i.d. was added. Two patients were enrolled at this dose level. Both experienced DLTs (1 patient had intolerable grade 2 anorexia and dysgeusia and grade 3 diarrhea; the other patient had intolerable grade 2 nausea and grade 3 fatigue).

Per the dose escalation scheme, no additional patients were enrolled in the 300 mg b.i.d. cohort; rather, 2 additional patients would have been required in the 200 mg b.i.d. cohort to establish an MTD. Given the notable extent of toxicities and difficulty with patient retention, a decision was made to close the trial.

Overall, treatment with BEZ235 was poorly tolerated: 50% of patients developed grade 3--4 adverse events ([Table 1](#T1){ref-type="table"}), and 50% of patients came off the study because of toxicities. No objective responses were observed in the five evaluable patients. Two of these patients had stable disease and three patients had progression as best response. Poor tolerance limited the ability to assess whether dual inhibition of PI3K and mTOR with BEZ235 is effective in patients with RCC. There is currently no evidence to support its continued investigation in this disease.

Trial Information {#s3}
=================

DiseaseRenal cell carcinoma -- clear cellDiseaseRenal cell carcinoma -- non-clear cellStage of disease / treatmentMetastatic / AdvancedPrior TherapyNo designated number of regimensType of study - 1Phase IType of study - 23 + 3Primary EndpointRecommended Phase II DosePrimary EndpointMaximum Tolerated DoseSecondary EndpointTolerabilitySecondary EndpointSafetyAdditional Details of Endpoints or Study DesignThis was originally designed as a phase Ib/II study; however, no patients were enrolled into the phase II part because of premature closure of the study.Investigator\'s AnalysisPoorly tolerated/not feasible

Drug Information {#s4}
================

Drug 1Generic/Working nameBEZ235Company nameNovartisDrug typeSmall moleculeDrug classmTOR inhibitorDoseMilligrams per flat doseRouteOralSchedule of AdministrationTwice daily

Dose Escalation Table {#s5}
=====================

Patient Characteristics {#s6}
=======================

Number of patients, male8Number of patients, female2StageIVAgeMedian (range): 62 years (47--76 years)Number of prior systemic therapiesMedian (range): 3 (2--5)Performance Status: ECOG0 --- 41 --- 62 --- 03 --- 0Unknown --- 0Cancer Types or Histologic SubtypesClear cell, 6Unclassified, 2Papillary, 1Chromophobe, 1

Primary Assessment Method {#s7}
=========================

**Control Arm: Total Patient Population**Number of patients screened15Number of patients enrolled10Number of patients evaluable for toxicity10Number of patients evaluated for efficacy5Response assessment CR*n* = 0 (0%)Response assessment PR*n* = 0 (0%)Response assessment SD*n* = 2 (20%)Response assessment PD*n* = 3 (30%)Response assessment OTHER*n* = 5 (50%)

Adverse Events {#s8}
==============

Serious Adverse Events {#s9}
======================

Dose-Limiting Toxicities {#s10}
========================

Assessment, Analysis, and Discussion {#s11}
====================================

CompletionStudy terminated before completionTerminated reasonToxicityInvestigator\'s AssessmentPoorly tolerated/not feasible

Although the mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus are approved for the treatment of advanced renal cell carcinoma (RCC), significant tumor reductions and prolonged responses are seen in only a minority of patients \[[@B1]--[@B3]\]. There are several proposed mechanisms of resistance that could account for their limited activity. First, inhibition of mammalian target of rapamycin complex 1 (mTORC1) has been shown to prompt feedback activation of PI3K/Akt, which, in turn, could also activate other kinases \[[@B4]\]. Second, mTOR exerts its multiple functions as part of two distinct multiprotein complexes, mTORC1 and mTORC2, both with defined pro-oncogenic roles in human cancer. Everolimus and temsirolimus are allosteric inhibitors of mTORC1 but leave mTORC2 unaffected. There is thought to be cross-talk between the two complexes; hence, inhibition of mTORC1 could result in compensatory upregulation of mTORC2 activity \[[@B5]\]. A third proposed mechanism involves activation of the mitogen-activated protein kinase signaling pathway via mTORC1 inhibition \[[@B6]\].

BEZ235 is a novel, orally available imidazoquinoline that potently and reversibly inhibits class I PI3K and mTOR kinase, hence suppressing downstream effects of both mTORC1 and mTORC2. BEZ235 has been demonstrated to inhibit its putative targets and block tumor growth in preclinical models of various malignancies \[[@B7], [@B8]\]. In RCC cell lines and xenografts, when compared with rapamycin, BEZ235 treatment resulted in greater reduction in tumor cell proliferation and more complete suppression of Akt and other pathways downstream of PI3K \[[@B9]\]. The first-in-human phase I study of BEZ235, in gelatin capsule form, in advanced solid tumors demonstrated high inter- and intrapatient pharmacokinetic variability \[[@B10]\]. A solid dispersion system sachet was developed to decrease variability, and a maximum tolerated dose (MTD) of 1600 mg once daily was established; however, the safety of twice daily dosing warranted further investigation \[[@B11]\]. In this phase Ib trial, we sought to investigate the safety of BEZ235 sachet twice daily in patients with advanced RCC.

The results of this trial highlight that promising preclinical data and sound biological rationale do not always translate into successful development of a novel agent. We encountered dose-limiting toxicities at all dose levels tested on the trial; no objective responses were seen. The trial was closed early because of poor tolerance, a recommended phase II dose was not defined, and a planned expansion cohort did not open.

The adverse event profile of the study drug was largely class specific (i.e., similar to what has been seen with other PI3K/TORC1/TORC2 inhibitors). The challenges around drug tolerance encountered in this trial with BEZ235 parallel the experience across other malignancies. A parallel phase I study of BEZ235 in sachet formulation given twice daily also showed considerable toxicity, although it established an MTD of 300 mg twice daily \[[@B12]\]. A phase II trial of BEZ235 with the same dosing regimen in transitional cell carcinoma showed modest clinical activity but an unfavorable toxicity profile, with 50% of patients experiencing grade 3--4 toxicities \[[@B13]\]. Another phase II trial of the drug at twice daily 300-mg or 400-mg doses in patients with advanced pancreatic neuroendocrine tumors also had a high rate of toxicity and did not proceed to further investigation \[[@B14]\].

The strategy of dual mTOR/PI3K inhibition for advanced RCC has been pursued with other agents. A randomized trial of GDC-0980, another dual pan-PI3K and MTORC1/2 inhibitor, versus everolimus in patients with metastatic RCC showed that GDC-0980 had a higher rate of grade 3--4 adverse events (31% vs. 12%), and did not show benefit compared with everolimus \[[@B15]\]. A randomized phase II trial of AZD2014, a dual TORC1/TORC2 inhibitor, compared with everolimus, in RCC reported better patient tolerance. The study suggested that the AZD2014 group had fewer grade 3--4 adverse events than the everolimus group \[[@B16]\]. Disappointingly, however, the trial was terminated early when an early interim analysis suggested inferior outcome with AZD2014, including for the primary endpoint of progression-free survival (hazard ratio: 2.8; 95% confidence interval: 1.2--6.5; *p* = .01), and potentially also for overall survival (hazard ratio: 3.1; 95% confidence interval: 1.1--8.4; *p* \< .02).

It seems unlikely that a challenging safety profile alone might account for such differences in cancer-specific outcome. Some have proposed that dual mTORC1/2 inhibition upregulates FOXO activity, which, in turn, may upregulate receptor tyrosine kinase expression \[[@B17], [@B18]\]. Regardless, in aggregate, our data do not support the strategy of broader mTOR/PI3K pathway inhibition in advanced RCC. Certainly, in the case of BEZ235, added target-specific toxicity got in the way of meaningful improvement in anticancer effect.
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